What is Leerink Partnrs’ Estimate for Celcuity Q2 Earnings?

Celcuity Inc. (NASDAQ:CELC) – Stock analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for Celcuity in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will earn ($0.85) per share for the quarter. The consensus estimate for Celcuity’s current full-year earnings is ($2.62) per share.

Other analysts have also recently issued research reports about the company. Needham & Company LLC upped their price objective on Celcuity from $23.00 to $29.00 and gave the company a “buy” rating in a research note on Thursday. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Celcuity in a research report on Friday, November 15th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $30.17.

Celcuity Stock Performance

CELC opened at $12.59 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 10.35 and a quick ratio of 10.36. Celcuity has a 1-year low of $10.35 and a 1-year high of $22.19. The company has a 50-day moving average of $12.31 and a 200-day moving average of $14.46.

Institutional Investors Weigh In On Celcuity

A number of hedge funds have recently added to or reduced their stakes in CELC. State Street Corp grew its position in shares of Celcuity by 152.2% during the third quarter. State Street Corp now owns 1,107,415 shares of the company’s stock worth $16,512,000 after acquiring an additional 668,318 shares during the last quarter. Braidwell LP increased its stake in shares of Celcuity by 71.2% in the third quarter. Braidwell LP now owns 884,306 shares of the company’s stock valued at $13,185,000 after purchasing an additional 367,663 shares during the period. Candriam S.C.A. bought a new stake in shares of Celcuity during the fourth quarter valued at approximately $3,450,000. Charles Schwab Investment Management Inc. boosted its position in shares of Celcuity by 226.2% during the third quarter. Charles Schwab Investment Management Inc. now owns 221,671 shares of the company’s stock worth $3,305,000 after buying an additional 153,712 shares during the period. Finally, Geode Capital Management LLC grew its holdings in Celcuity by 27.6% in the 3rd quarter. Geode Capital Management LLC now owns 630,369 shares of the company’s stock worth $9,401,000 after buying an additional 136,518 shares in the last quarter. 63.33% of the stock is currently owned by institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.